Search

Your search keyword '"Feldmeyer, L"' showing total 244 results
Start Over Author "Feldmeyer, L"
244 results on '"Feldmeyer, L"'

2. Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus

Author

Lande, R., Palazzo, R., Gestermann, N., Jandus, C., Falchi, M., Spadaro, F., Riccieri, V., James, E. A., Butera, A., Boirivant, M., Feldmeyer, L., Surbeck, I., Di Lucca, J., Stuber, F., Spinelli, F. R., Botti, E., Marinari, B., Bianchi, L., Pica, R., Cerbelli, B., Giannakakis, K., Auteri, S. E., Daniels, I., Durrant, L. G., Horstman, S., Costanzo, A., Romero, P., Alessandri, C., Conti, F., Valesini, G., Gilliet, M., Chizzolini, C., and Frasca, L.

Published
2020
Full Text
View/download PDF

3. Pain Identifies Squamous Cell Carcinoma in Organ Transplant Recipients: The SCOPE-ITSCC PAIN Study

Author

Bouwes Bavinck, J.N., Harwood, C.A., Genders, R.E., Wisgerhof, H.C., Plasmeijer, E.I., Mitchell, L., Olasz, E.B., Mosel, D.D., Pokorney, M.S., Serra, A.L., Feldmeyer, L., Baumann Conzett, K., Piaserico, S., Belloni Fortina, A., Jahn, K., Geusau, A., Gerritsen, M.J.P., Seçkin, D., Güleç, A.T., Cetkovská, P., Ricar, J., Imko-Walczuk, B., Proby, C.M., and Hofbauer, G.F.L.

Published
2014
Full Text
View/download PDF

4. Survie globale et prise en charge du syndrome de Sézary : étude rétrospective multicentrique de 402 cas

Author

Bozonnat, A., primary, Beylot-Barry, M., additional, Dereure, O., additional, D’Incan, M., additional, Quéreux, G., additional, Guenova, E., additional, Grange, F., additional, Viguier, M., additional, Ram-Wolff, C., additional, Boulinguez, S., additional, Troin, L., additional, Montaudié, H., additional, Feldmeyer, L., additional, Beltraminelli, H., additional, Bonnet, N., additional, Maubec, E., additional, Franck, N., additional, Machet, L., additional, Chasset, F., additional, Saiag, P., additional, Hainault, E., additional, Brunet Possenti, F., additional, Michel, C., additional, Bens, G., additional, Adamski, H., additional, Aubin, F., additional, Faiz, S., additional, Mortier, L., additional, Joly, P., additional, Tedbirt, B., additional, Templier, I., additional, Bouaziz, J.D., additional, Battistella, M., additional, Oro, S., additional, Bagot, M., additional, Serret-Larmande, A., additional, Montlahuc, C., additional, and de Masson, A., additional

Published
2022
Full Text
View/download PDF

9. Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus

Author

Utz, S, Suter, V G A, Cazzaniga, S, Borradori, L, and Feldmeyer, L

Subjects
610 Medizin und Gesundheit
Abstract

BACKGROUND AND OBJECTIVE Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme. METHODS Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission, no response), subjective impairment by a 3-point scale (severe, moderate, none). RESULTS Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months, respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment, respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months, respectively. 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developped a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects. CONCLUSION Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.

Published
2022
Full Text
View/download PDF

33. Development of pemphigus vulgaris following mRNA SARS‐CoV‐19 BNT162b2 vaccination in an 89‐year‐old patient.

Author

Knechtl, G.V., Seyed Jafari, S.M., Berger, T., Rammlmair, A., Feldmeyer, L., and Borradori, L.

Subjects
PEMPHIGUS vulgaris, PEMPHIGUS, COVID-19 vaccines, VACCINATION, MESSENGER RNA, BULLOUS pemphigoid
Abstract

The patient has provided written consent for the publication of the case. Most PV patients are aged 40-60 years at diagnosis.1 The mean age of pemphigus patients was 62.5 years in the Swiss cohort.3 However, the development of PV after COVID-19 vaccination may be simply coincidental in our patient. Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient. [Extracted from the article]

Published
2022
Full Text
View/download PDF

38. Oral lichen planus and oral lichenoid lesions – an analysis of clinical and histopathological features.

Author

Feldmeyer, L., Suter, V.G., Oeschger, C., Cazzaniga, S., Bornstein, M.M., Simon, D., Borradori, L., and Beltraminelli, H.

Subjects
*ORAL lichen planus, *LICHEN planus, *FISHER exact test
Abstract

Oral lichen planus (OLP) and oral lichenoid lesions (OLL) share several clinical and histopathological characteristics; therefore, it is often difficult to distinguish between them. Lichen planus (LP) is an idiopathic inflammatory disease of the skin, hair follicle, nails and mucous membranes.[1] Cutaneous lichen planus (CLP) was observed in up to 20% of an OLP population,[2] and more than 50% of patients with CLP have concomitant OLP.[3] There is another group of oral inflammatory lesions with both clinically and histopathologically similar characteristics as OLP, but which not compatible with OLP and are typically associated with an attributable aetiological factor. [Extracted from the article]

Published
2020
Full Text
View/download PDF

42. Not all intravenous immunoglobulin preparations are equally well tolerated

Author

Feldmeyer, L, Benden, C, Haile, S R, Boehler, A, Speich, R, French, L E, Hofbauer, F G L, University of Zurich, and Feldmeyer, L

Subjects
2708 Dermatology, 10177 Dermatology Clinic, 610 Medicine & health, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), 10029 Clinic and Policlinic for Internal Medicine, 10178 Clinic for Pneumology
Published
2010

43. A relapsing localized variant of neutrophilic dermatosis triggered by tissue injury.

Author

Gloor, A.D., Feldmeyer, L., Rammlmair, A., Schlapbach, C., Wallach, D., and Borradori, L.

Subjects
*SOFT tissue injuries, *BUTTOCKS, *SKIN diseases, *DIAGNOSIS, *DISEASE complications
Abstract

Dear Editor, Neutrophilic dermatoses (NDs) comprise a group of autoinflammatory disorders characterized by a neutrophilic-rich infiltrate in the skin. Histology showed dermal oedema with an interstitial and perivascular neutrophilic infiltrate with some foci of diapedesis. [Extracted from the article]

Published
2021
Full Text
View/download PDF

45. The yellow clod sign

Author

Navarini, A A, Feldmeyer, L, Töndury, B, Fritsche, P, Kamarashev, J, French, L E, Braun, R P, University of Zurich, and Navarini, A A

Subjects
2708 Dermatology, 10177 Dermatology Clinic, 610 Medicine & health
Published
2011

49. Interleukin-1, inflammasomes and the skin

Author

Feldmeyer, L, Werner, S, French, L E, Beer, H D, and University of Zurich

Subjects
2734 Pathology and Forensic Medicine, 1307 Cell Biology, 10177 Dermatology Clinic, 610 Medicine & health, 2722 Histology
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results